Carisoprodol

Summary

Carisoprodol (CHEMBL1233) is an approved small-molecule muscle relaxant (ATC M03BA72); indicated across 3 conditions.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M03BA72 (+2 more)
• Indications: 3 conditions
• Chemistry: 260.33 Da · C12H24N2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1233
Name	Carisoprodol
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	2576
ChEBI	CHEBI:3419
ATC	M03BA72, M03BA02, M03BA52
Molecular formula	C12H24N2O4
Molecular weight	260.33
InChIKey	OFZCIYFFPZCNJE-UHFFFAOYSA-N

SMILES: CCCC(C)(COC(=O)N)COC(=O)NC(C)C

IUPAC name: [2-(carbamoyloxymethyl)-2-methylpentyl] N-propan-2-ylcarbamate

ChEBI definition: A carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm.

Pharmacological roles (ChEBI): muscle relaxant.

Also known as: Carisoma, Carisoprodol, Carisoprodol civ, Carisoprodol component of compound, Carisoprodol component of soma compound, NSC-172124, Rela, Soma, carisoprodol, SID17389120, SID50105222, SID855912

Patent coverage: 18,321 distinct patent families (37,387 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Prelamin-A/C, Ras-related protein Rab-9A, Thyrotropin receptor, Alpha-1A adrenergic receptor, Muscarinic acetylcholine receptor M1, Nuclear factor NF-kappa-B p105 subunit, Cytochrome P450 3A4.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	8.25	Potency	5.6	nM	CHEMBL_ACT_3644249
P08482	7	Potency	100	nM	CHEMBL_ACT_4803349
TSHR	6.2	Potency	631	nM	CHEMBL_ACT_3920017
TSHR	6.2	Potency	631	nM	CHEMBL_ACT_4617586
TDP1	6.1	Potency	794.3	nM	CHEMBL_ACT_3930648
RAB9A	5.2	Potency	6310	nM	CHEMBL_ACT_3848299

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (2 at ChEMBL trial phase 4).

The 3 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 2 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).